Synbiotic Health reports new health benefits for flagship probiotic B. adolescentis strain

13-Jun-2023 - Last updated on 13-Jun-2023 at 14:23 GMT

Nebraska-based Synbiotic Health has reported data from genomic evaluation in vitro testing that reveals that B. adolescentis, iVS-1, produces gamma-aminobutyric acid (GABA) and Folate, expanding the strain’s known attributes and representing an enhanced value proposition.

GABA is a well-documented neurotransmitter with stress-reducing and sleep enhancing effects via interaction at the gut/brain barrier. GABA is found to positively modulate mood and sleep, increase spatial and temporal memory, and reduce hypertension.

Folate has been proven to provide numerous health benefits. It is well known for its positive impact on heart health and is essential during pregnancy to support normal growth and development of the fetus. Folate is required for DNA replication, repair, and methylation.

The company’s data indicated that iVS-1 produced 3X more folate than other strains analyzed and was found to produce a more bioavailable form of folate compared to the folic acid found in most dietary supplement products.

“These findings represent an important milestone for Synbiotic and our customers,” said Steve Prescott, Synbiotic’s Chief Commercial Office. “Demonstrating that iVS-1has the ability to produce both GABA and folate is an exciting development, since these metabolites are known to positively impact human health through multiple modes of action.”

Prescott told NutraIngredients-USA that the data on folate and GABA is preclinical lab data.

“Both the folate and GABA data were obtained using validated labs methods and are intended to give Synbiotic Health confidence that these products will be successful if/when we move forward with a clinical study,” he said.

Kevin Hooper, Director of Business Development at Synbiotic Health, added: “When taken together with the already known attributes of iVS-1, including its proliferation and persistence at high levels in the human gut, its ability to promote a bifidogenic response, and its capacity to promote healthy gut-barrier function all at low levels of supplementation (1 billion cfu/dose), iVS-1 becomes a strong addition to many probiotic products designed for a variety of health claims.”

Commercialization

Development and commercialization of these probiotic ingredients will be supported by Synbiotic Health’s previously announced expansion in Madison, Wisconsin, said the company. The new 43,000 sq. ft. facility, scheduled to open in late 2023 or early 2024, is designed to help consumer brands bring high quality probiotic products to market more quickly and efficiently than the competition.

“We are extremely excited for the opportunity to commercialize these strains, and we are looking forward to future developments from our innovative, forward-thinking R&D team. Bringing new and impactful health benefits to market and to the consumer is what drives us at Synbiotic Health,” added Prescott.